Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Burning Rock Biotech (BNR) Total Debt (2019 - 2025)

Burning Rock Biotech has reported Total Debt over the past 4 years, most recently at $267885.9 for Q4 2025.

For Q4 2025, Total Debt changed N/A year-over-year to $267885.9; the TTM value through Dec 2025 reached $267885.9, changed N/A, while the annual FY2025 figure was $267885.9, N/A changed from the prior year.
Total Debt for Q4 2025 was $267885.9 at Burning Rock Biotech, up from $251492.2 in the prior quarter.
Over five years, Total Debt peaked at $5.0 million in Q1 2021 and troughed at $251492.2 in Q3 2025.